Related Experiment Video
Updated: May 11, 2026
08:51
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
Published on: March 1, 2013
15.8K
Esterase-responsive nanoparticles (ERN): A targeted approach for drug/gene delivery exploits
Ashok Kumar Madikonda1, Amritha Ajayakumar1, Sudeena Nadendla2
1Department of Biochemistry & Molecular Biology, Central University of Kerala, Tejaswini Hills, Periye, Kasaragod 671320, Kerala, India.
Bioorganic & Medicinal Chemistry
|November 18, 2024
Summary
Esterase-responsive nanoparticles improve cancer drug delivery by targeting tumors more specifically. This approach enhances therapeutic payload release at the tumor site, minimizing side effects and improving treatment efficacy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Nanoparticles enhance drug delivery to tumors via the enhanced permeability and retention (EPR) effect.
- Traditional nanoparticles lack specificity, causing inefficient delivery and side effects.
- Esterase-responsive nanoparticles offer targeted drug release at tumor sites.
Purpose of the Study:
- Review the role of esterase-responsive nanoparticles in drug and gene delivery.
- Examine esterase prodrug therapy.
- Discuss the application of PSMA-targeted esterase-responsive nanoparticles in prostate cancer.
Main Methods:
- Literature review of esterase-responsive nanoparticles in cancer therapy.
- Analysis of esterase activity for targeted drug release mechanisms.
- Evaluation of prostate-specific membrane antigen (PSMA) as a target for nanoparticle delivery.
Main Results:
- Esterase-responsive nanoparticles demonstrate improved targeting and payload release in tumors.
- Esterase prodrug strategies show potential for localized cancer treatment.
- PSMA-targeted nanoparticles show promise for prostate cancer therapy.
Conclusions:
- Esterase-responsive nanoparticles represent a promising strategy for targeted cancer drug and gene delivery.
- Further research is needed to optimize these systems for clinical application.
- These targeted nanoparticles hold significant potential for improving cancer treatment outcomes.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...